Literature DB >> 15459178

Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status.

Takeshi Hirota1, Ichiro Ieiri, Hiroshi Takane, Shinji Maegawa, Masakiyo Hosokawa, Kaoru Kobayashi, Kan Chiba, Eiji Nanba, Mitsuo Oshimura, Tetsuo Sato, Shun Higuchi, Kenji Otsubo.   

Abstract

The human cytochrome P450 3A4 (CYP3A4) plays a dominant role in the metabolism of numerous clinically useful drugs. Alterations in the activity or expression of this enzyme may account for a major part of the variation in drug responsiveness and toxicity. However, it is generally accepted that most of the known single nucleotide polymorphisms in the coding and 5'-flanking regions are not the main determinants for the large inter-individual variability of CYP3A4 expression and activity. We show that the allelic variation is critically involved in determining the individual total hepatic CYP3A4 mRNA level and metabolic capability. There exists a definite correlation between the total CYP3A4 mRNA level and allelic expression ratio, the relative transcript level ratio derived from the two alleles. Individuals with a low expression ratio, exhibiting a large difference of transcript level between the two alleles, revealed extremely low levels of total hepatic CYP3A4 mRNA, and thus low metabolic capability as assessed by testosterone 6beta-hydroxylation. These results present a new insight into the individualized CYP3A4-dependent pharmacotherapy and the importance of expression imbalance to human phenotypic diversity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459178     DOI: 10.1093/hmg/ddh313

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

1.  Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.

Authors:  Chang Sun; Catherine Southard; David B Witonsky; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

2.  Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphisms.

Authors:  Hong Wu; Xiuling Zhang; Guoyu Ling; Jaime D'Agostino; Xinxin Ding
Journal:  Pharmacogenet Genomics       Date:  2009-11       Impact factor: 2.089

3.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.

Authors:  D Wang; Y Guo; S A Wrighton; G E Cooke; W Sadee
Journal:  Pharmacogenomics J       Date:  2010-04-13       Impact factor: 3.550

4.  MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients.

Authors:  Keiko Hosohata; Satohiro Masuda; Atsushi Yonezawa; Toshiya Katsura; Fumitaka Oike; Yasuhiro Ogura; Yasutsugu Takada; Hiroto Egawa; Shinji Uemoto; Ken-Ichi Inui
Journal:  Pharm Res       Date:  2009-03-07       Impact factor: 4.200

5.  Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.

Authors:  Lauren L Richards-Waugh; Donald A Primerano; Yulia Dementieva; James C Kraner; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2014-10       Impact factor: 3.367

Review 6.  Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Authors:  Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

7.  Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells.

Authors:  Lili Milani; Manu Gupta; Malin Andersen; Sumeer Dhar; Mårten Fryknäs; Anders Isaksson; Rolf Larsson; Ann-Christine Syvänen
Journal:  Nucleic Acids Res       Date:  2007-01-31       Impact factor: 16.971

Review 8.  A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challenges.

Authors:  Mitsuo Oshimura; Narumi Uno; Yasuhiro Kazuki; Motonobu Katoh; Toshiaki Inoue
Journal:  Chromosome Res       Date:  2015-02       Impact factor: 5.239

9.  Intergenic, gene terminal, and intragenic CpG islands in the human genome.

Authors:  Yulia A Medvedeva; Marina V Fridman; Nina J Oparina; Dmitry B Malko; Ekaterina O Ermakova; Ivan V Kulakovskiy; Andreas Heinzel; Vsevolod J Makeev
Journal:  BMC Genomics       Date:  2010-01-19       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.